OCT 05, 2018 9:00 AM PDT

FDA approves a new drug for an advanced type of skin cancer

WRITTEN BY: Heba El Wassef

As cancer is one of the most challenging diseases in our world, many efforts have been put into researching new ways for treatment to find new drugs that could help more patients worldwide. Anticancer immunotherapy drugs are one class of drugs that have been developed recently and that have successfully helped in treating different types of cancers, no wonder that the Nobel prize in medicine/physiology this year has been awarded to the two doctors who contributed in discovering this class. 

Using PD-1/PD-L1 against cancer in immunotherapy, Credit: abcam

Recently the U.S. Food and Drug Administration has approved a new drug called Libtayo (cemiplimab-rwlc) which is a member of the anticancer immunotherapy class of drugs, it is an injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who cannot be treated with surgery or radiation.

This drug is the first and only drug to treat this type of skin cancer (CSCC) which is the second most common type of cancer in the United States and represents 20% of all non-melanoma skin cancer. It is usually developed by regular exposure to the sun or ultraviolet radiation. It can cause disfigurement and other local complications as bleeding or infection. Also, it can metastasize to other organs in the body which can make it life-threatening.

Libtayo works by blocking the PD-1 / PD-L1 pathway, by doing this it can help the immune system fights cancer.

The PD-1 is a protein receptor expressed on T-cells, it binds to its ligand PD-L1 which is commonly expressed on macrophages and dendritic cells. They both belong to the family of checkpoints that function to ensure that the immune system only reacts at the right time.

Cancer cells express a PD-L1 receptor that after binding to PD-1, this inhibits T cells making them unable to destroy the cancer cells and they keep on growing.

Two open-label clinical trials were done to study the efficacy and safety of Libtayo with 108 patients included (75 with metastatic disease and 33 with the locally-advanced disease). The results showed that the tumors shrunk or disappeared in 47.2% of all patients treated.

Libtayo side effects include fatigue, rash, and diarrhea. It can also cause severe or life-threatening side effects due to its effect on normal tissues and organs that can impair their functions, like lung problems (pneumonitis), intestinal problems (colitis), liver problems (hepatitis), hormone gland problems (endocrinopathies), skin (dermatologic) problems and kidney problems. Patients should also be monitored for infusion-related reactions.

It is not safe in pregnancy as it can cause harm to the fetus.

“We are continuing to see a shift in oncology toward identifying and developing drugs aimed at a specific molecular target. With the Libtayo approval, the FDA has approved six immune checkpoint inhibitors targeting the PD-1 / PD-L1 pathway for treating a variety of tumors, from bladder to head and neck cancer, and now advanced CSCC,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “This type of cancer can be difficult to treat effectively when it is advanced, and it is important that we continue to bring new treatment options to patients.”

Watch the video below to learn more about cancer immunotherapy.

Source: FDA, abcam

About the Author
  • A master student in Biochemistry and Molecular biology with experience in Education and Research. I am passionate about scientific research and passing my knowledge to others to help them learn about the latest in science by teaching, writing and volunteering in scientific events.
You May Also Like
FEB 01, 2021
Cancer
Nanoparticle drug delivery to treat pancreatic cancer
FEB 01, 2021
Nanoparticle drug delivery to treat pancreatic cancer
Research published last month in the journal Molecular Pharmaceutics details a new mechanism for delivering pancreatic c ...
FEB 12, 2021
Cancer
A behavioral science approach to FIT kits
FEB 12, 2021
A behavioral science approach to FIT kits
Researchers from the Perelman School of Medicine at the University of Pennsylvania have a new strategy to promoting colo ...
FEB 24, 2021
Cancer
Inducing ferroptosis in neuroblastoma cells
FEB 24, 2021
Inducing ferroptosis in neuroblastoma cells
New research published in the journal Cancer Research describes the process by which iron can trigger cell death in ...
FEB 23, 2021
Cancer
Quantifying cancer survivors' stress during the early months of the pandemic
FEB 23, 2021
Quantifying cancer survivors' stress during the early months of the pandemic
Approximately one-third of cancer survivors were psychologically distressed during the early months of the pandemic due ...
MAR 23, 2021
Cancer
Examining the role that cholesterol plays in brain cancer
MAR 23, 2021
Examining the role that cholesterol plays in brain cancer
A study published recently in the journal Nature Communications reports on the role that cholesterol plays in the g ...
APR 19, 2021
Cancer
Understanding why pacreatic cancer metastasizes
APR 19, 2021
Understanding why pacreatic cancer metastasizes
New research published in the journal Gastroenterology reports on the mechanisms of metastatic pancreatic cancer cells, ...
Loading Comments...